Marks Group Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Marks Group Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$546K	Buy	+1,650	New	+$561K	0.05%	236

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marks Group Wealth Management's ALNY Position: Q1 2026 in Review

Marks Group Wealth Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q1 2026: 1,650 shares worth $546K. The stake represents 0.05% of the portfolio and ranks #236 among its holdings.

786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Marks Group Wealth Management held 1,650 shares of Alnylam Pharmaceuticals worth $546K as of Q1 2026.
Alnylam Pharmaceuticals was a new Marks Group Wealth Management position in Q1 2026.
Alnylam Pharmaceuticals made up 0.05% of Marks Group Wealth Management's portfolio in Q1 2026, its #236 holding.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Marks Group Wealth Management's 13F filing for Q1 2026, filed 5 May 2026.